Health

Three COVID-19 Vaccines Under Final Review For Emergency Use – WHO

According to Reuters, the World Health Organization (WHO) reported on Wednesday that, in addition to the one already approved by Pfizer and BioNTech, three COVID-19 vaccines were in the late stages of the analysis for future emergency use listings.

An internal WHO document seen by Reuters offers timelines for potential vaccine approvals from the agency, suggesting that in coming weeks or months, shots from Moderna, AstraZeneca, and China’s Sinopharm and Sinovac could receive the emergency go-ahead.

“We have one vaccine so far listed. We have 3 more in the final phase to be assessed for listing, we have 2 more still submitting…In total, we have 13,” Mariangela Simao, WHO assistant director-general for access to medicines, vaccines, and pharmaceuticals.

No deaths related to the Pfizer vaccine or any other vaccine is known to the WHO, she added.

Source: Reuters

Adib Mohd

Recent Posts

Pullman Kuching Introduces “Where Hope Rises” and Ramadan Buffet 2026

This year, Pullman Kuching isn’t just rolling out another buffet poster. They’re introducing “Where Hope… Read More

2 days ago

Do Exams Actually Help Our Kids or Just Stress Them Out?

Okay, so everyone's talking about exams again. And no, it's not because we're all secretly… Read More

3 days ago

Why Cancer Survivorship Must Protect the Heart Too

The end of cancer treatment often feels like the final scene of a long drama.… Read More

3 days ago

Tesla Malaysia Completes First Official Vehicle Delivery in East Malaysia

Tesla Malaysia marks a major milestone today with its first official delivery of Tesla vehicles… Read More

4 days ago

PUBG MOBILE Launches Spring Festival Featuring Lion Dance and Community Activities

Huat Ah! PUBG MOBILE, one of the world’s most popular mobile games, is ushering in… Read More

4 days ago

Tuberculosis (TB), The Persistent Disease That Refuses to Disappear

Let’s be real. When you’ve got a cough that just won’t quit, it’s easy to… Read More

4 days ago

This website uses cookies.